Free tool
FAERS Monitor: Lemtrada
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103948 or its brand name (Lemtrada, Alemtuzumab). Reports on generic versions are filed under their own applications.
Reports
19,365
Serious
16,665
86% of reports
Hospitalization
6,156
Death reported
2,947
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache1,906
- fatigue1,874
- pyrexia1,784
- off label use1,698
- rash1,200
- nausea1,190
- drug ineffective1,032
- dyspnoea985
- asthenia942
- multiple sclerosis relapse923
- lymphocyte count decreased879
- cytomegalovirus infection839
- urinary tract infection835
- pain755
- condition aggravated725
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 153 |
| 2005 | 150 |
| 2006 | 150 |
| 2007 | 189 |
| 2008 | 336 |
| 2009 | 373 |
| 2010 | 363 |
| 2011 | 704 |
| 2012 | 320 |
| 2013 | 427 |
| 2014 | 486 |
| 2015 | 985 |
| 2016 | 1,627 |
| 2017 | 1,750 |
| 2018 | 2,274 |
| 2019 | 2,380 |
| 2020 | 1,690 |
| 2021 | 1,288 |
| 2022 | 1,072 |
| 2023 | 849 |
| 2024 | 738 |
| 2025 | 635 |
| 2026 | 425 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,794 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytomegalovirus infectionSignal | 839 | 57.7 | 53.9 | 44,361 |
| lymphocyte count decreasedSignal | 879 | 56.8 | 53.1 | 45,767 |
| multiple sclerosis relapseSignal | 923 | 14.8 | 13.9 | 11,753 |
| pyrexiaSignal | 1,784 | 5.6 | 5.4 | 6,855 |
| urinary tract infectionSignal | 835 | 5.3 | 5.0 | 2,949 |
| headacheSignal | 1,906 | 3.3 | 3.2 | 3,153 |
| rashSignal | 1,200 | 3.0 | 2.8 | 1,622 |
| astheniaSignal | 942 | 2.7 | 2.6 | 1,043 |
| fatigueSignal | 1,874 | 2.6 | 2.5 | 1,940 |
| condition aggravatedSignal | 725 | 2.6 | 2.4 | 717 |
| off label useSignal | 1,698 | 2.1 | 2.0 | 1,029 |
| dyspnoea | 985 | 1.9 | 1.8 | 424 |
| nausea | 1,190 | 1.6 | 1.5 | 303 |
| pain | 755 | 1.3 | 1.2 | 65 |
| drug ineffective | 1,032 | 0.9 | 0.8 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.